AbbVie Buys Apogee for $10.9 Billion in Its Biggest Deal in Over Five Years
AbbVie announced on Monday it will acquire Apogee Therapeutics for $10.9 billion, its biggest deal in more than five years. The acquisition is part of AbbVie's strategy to expand its next-generation immunology pipeline. Apogee's experimental drugs are intended to bolster AbbVie's portfolio as patents on key existing products expire.
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!